The future of cardiac tissue
engineering has arrived


Myocardial Infarction (MI) occurs when a part of the heart muscle does not receive enough blood flow, causing heart muscle damage. Approximately 1.5 million MI cases occur annually in the United States. MI healthcare costs are extremely high, ranked in the top five most expensive conditions for inpatient hospitalizations.

Traditional MI treatment includes cardiac catheterization, coronary bypass or medications. In some cases, the tissue damage is irreversible and heart function deteriorates.

Existing regenerative solutions are partially synthetic or animal-derived, which limit tissue integration and have a high rate of immune rejection and potential scarring. Matricelf introduces next-generation regenerative medicine capable of producing completely autologous heart implants – for better tissue integration and minimal immune system response.

Matricelf has pioneered an efficient method to deliver vascularized tissue by injection of omental hydrogel to the infarcted heart tissue. The personalized thermo-responsive hydrogel maintains liquid form at room temperature. When injected into the infarcted heart, the hydrogel solidifies and physically cross-links to the heart tissue.

3D printed, biocompatible vascularized cardiac patches from ECM-based hydrogel

Hydrogels are widely used materials in tissue engineering. However, once the cells are encapsulated within hydrogels, mass transfer to the core of the engineered tissue is limited, and cell viability is compromised.

Matricelf’s proprietary technology enables the production of autologous, patient-specific hydrogels based on omental ECM. The omentum-based hydrogel is used to create autologous implants, where both ECM and the cells are produced from the patient’s omental biopsy.

Our proprietary technology enables the personalized hydrogel to be used as a bio-ink in 3D printing of tissues and organs. When combined with patient cells, the hydrogel is used to print tissues and organs that fully match the immunological, biochemical and anatomical properties of the patient.

Patch dimensions and the blood vessel geometry are designed with computer‐aided design (CAD) software using anatomical data from CT images. Blood vessel architecture is further improved by mathematical modeling of oxygen transfer. Smaller blood vessels can be added to the basic vasculature design to ensure adequate exposure of the cardiac patch to oxygenated medium during in vitro cultivation and after transplantation.